<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.4//EN" "ep-patent-document-v1-4.dtd">
<ep-patent-document id="EP04810417B8W1" file="EP04810417W1B8.xml" lang="en" country="EP" doc-number="1682177" kind="B8" correction-code="W1" date-publ="20100901" status="c" dtd-version="ep-patent-document-v1-4">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESI....FIRO..CY..TRBGCZEEHUPLSK....IS..............................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>DIM360 Ver 2.15 (14 Jul 2008) -  2999001/0</B007EP></eptags></B000><B100><B110>1682177</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20100901</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>04810417.8</B210><B220><date>20041104</date></B220><B240><B241><date>20060601</date></B241><B242><date>20070327</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>517337 P</B310><B320><date>20031104</date></B320><B330><ctry>US</ctry></B330><B310>525579 P</B310><B320><date>20031126</date></B320><B330><ctry>US</ctry></B330><B310>565710 P</B310><B320><date>20040427</date></B320><B330><ctry>US</ctry></B330><B310>611794 P</B310><B320><date>20040921</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20100901</date><bnum>201035</bnum></B405><B430><date>20060726</date><bnum>200630</bnum></B430><B450><date>20100721</date><bnum>201029</bnum></B450><B452EP><date>20100111</date></B452EP><B480><date>20100901</date><bnum>201035</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61K  39/395       20060101AFI20050523BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>VERWENDUNG VON ANTAGONISTEN-ANTI-CD40-ANTIKÖRPERN ZUR BEHANDLUNG VON CHRONISCH LYMPHOZYTISCHER LEUKÄMIE</B542><B541>en</B541><B542>USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA</B542><B541>fr</B541><B542>UTILISATION D'ANTICORPS ANTI-CD40 ANTAGONISTES POUR LE TRAITEMENT DE LA LEUCEMIE LYMPHOCYTIQUE CHRONIQUE</B542></B540><B560><B561><text>WO-A-01/83755</text></B561><B561><text>WO-A-02/28480</text></B561><B561><text>WO-A-02/28904</text></B561><B561><text>WO-A-02/088186</text></B561><B562><text>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2002 (2002-08), ELLMARK PETER ET AL: "Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library" XP002326955 Database accession no. PREV200200495981 &amp; IMMUNOLOGY, vol. 106, no. 4, August 2002 (2002-08), pages 456-463, ISSN: 0019-2805</text></B562><B562><text>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), WENG WEN-KAI ET AL: "Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma" XP002326956 Database accession no. PREV200200241215 &amp; BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 466a, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001 ISSN: 0006-4971</text></B562><B562><text>BALINT ROBERT., LARRICK JAMES: "Antibody engineering by parsimonious mutagenesis" GENE, vol. 137, 27 December 1993 (1993-12-27), pages 109-118,</text></B562><B562><text>LITTLE M. ET AL.: "Of mice and men: hybridoma and recombinant antibodies" REVIEW IMMUNOLOGY TODAY, vol. 21, August 2000 (2000-08), pages 364-370,</text></B562></B560></B500><B600><B620EP><parent><cdoc><dnum><anum>10007491.3</anum></dnum><date>20100720</date></cdoc></parent></B620EP></B600><B700><B720><B721><snm>LONG, Li</snm><adr><str>Chiron Corporation, P.O. Box 8097</str><city>Emeryville, CA 94662-8097</city><ctry>US</ctry></adr></B721><B721><snm>LUQMAN, Mohammad</snm><adr><str>Chiron Corporation, P.O. Box 8097</str><city>Emeryville, CA 94662-8097</city><ctry>US</ctry></adr></B721><B721><snm>YABANNAVAR, Asha</snm><adr><str>Chiron Corporation, P.O. Box 8097</str><city>Emeryville, CA 94662-8097</city><ctry>US</ctry></adr></B721><B721><snm>ZAROR, Isabel</snm><adr><str>Chiron Corporation, P.O. Box 8097</str><city>Emeryville, CA 94662-8097</city><ctry>US</ctry></adr></B721><B721><snm>AUKERMAN, Sharon, Lea</snm><adr><str>Chiron Corporation, P.O. Box 8097</str><city>Emeryville, CA 94662-8097</city><ctry>US</ctry></adr></B721></B720><B730><B731><snm>Novartis Vaccines and Diagnostics, Inc.</snm><iid>100788406</iid><irf>P043985EP</irf><adr><str>4560 Horton Street</str><city>Emeryville, CA 94608</city><ctry>US</ctry></adr></B731><B731><snm>XOMA Technology Ltd.</snm><iid>101111114</iid><irf>P043985EP</irf><adr><str>Clarendon House 
2 Church Street</str><city>Hamilton HM11</city><ctry>BM</ctry></adr></B731></B730><B740><B741><snm>Marshall, Cameron John</snm><sfx>et al</sfx><iid>100045777</iid><adr><str>Carpmaels &amp; Ransford 
One Southampton Row</str><city>London
WC1B 5HA</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>MC</ctry><ctry>NL</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>US2004036954</anum></dnum><date>20041104</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2005044304</pnum></dnum><date>20050519</date><bnum>200520</bnum></B871></B870></B800></SDOBI>
</ep-patent-document>
